Latest news with #EVT
Yahoo
2 days ago
- Business
- Yahoo
Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033
The stroke market is experiencing unprecedented growth, fueled by intense corporate investment and disruptive technologies like AI. This surge is rapidly advancing diagnostic speed and therapeutic options, fundamentally transforming the entire continuum of patient care. Chicago, July 17, 2025 (GLOBE NEWSWIRE) -- The global stroke diagnostic and therapeutic market was valued at US$ 42.07 billion in 2024 and is expected to reach US$ 81.68 billion by 2033, growing at a CAGR of 7.65% during the forecast period 2025–2033. Within the stroke diagnostic and therapeutic market, the segment for endovascular therapy (EVT) is experiencing unprecedented growth, solidified by a wave of compelling clinical evidence. A significant recent development involves a standardized, image-guided neurosurgical technique for clot removal in intracerebral hemorrhage, which has been shown to substantially improve patient outcomes; remarkably, the number needed to treat to achieve functional independence with this method is just eight patients. For ischemic stroke patients with large vessel occlusion and an extensive ischemic core, the benefits of EVT are now undisputed, with five randomized controlled trials confirming less disability compared to medical management alone. Request Sample Copy: The positive data is quantifiable, showing that for every 100 patients treated with EVT, an additional 17 achieve a better functional outcome and six more lives are saved. Further refining the treatment protocol, a post hoc analysis has revealed that administering intravenous thrombolysis (IVT) less than 140 minutes before EVT significantly boosts positive results. This efficacy extends to more distal blockages, as highlighted by a French registry on distal M2 MCA occlusions which reported successful reperfusion in 85% of patients undergoing EVT. The therapeutic landscape is also shifting, as five phase 3 trials have now established the noninferiority of tenecteplase when compared directly to alteplase, a change poised to significantly impact the stroke diagnostic and therapeutic market. Key Findings in Stroke Diagnostics and Therapeutics Market Market Forecast (2033) US$ 81.68 billion CAGR 7.65% Largest Region (2024) North America (29%) By Type Diagnostics (56.31%) By Application Ischemic Stroke (62.27%) Top Drivers Increasing global prevalence of stroke and associated risk factors Technological advancements in diagnostic imaging and minimally invasive therapies Rising healthcare expenditure and awareness of early stroke diagnosis Top Trends Growing adoption of artificial intelligence in stroke diagnosis Shift towards minimally invasive endovascular treatment procedures Expansion of telemedicine and remote tele-stroke services Top Challenges Stringent regulatory approvals for new devices and therapeutics Pharmaceutical Pipeline for Ischemic Stroke Explodes with Over 200 Novel Drugs The pharmaceutical pipeline is a highly competitive and lucrative corner of the stroke diagnostic and therapeutic market. The sheer scale of this research and development effort is immense, with over 50 companies actively working on more than 55 distinct pipeline drugs. In total, the current ischemic stroke pipeline features an impressive 202 drugs in various stages of development from 182 different companies and institutions, a testament to the vibrancy of the stroke diagnostic and therapeutic market. The preclinical stage is currently the most active area of innovation, with 76 unique drugs being investigated, signaling a robust future for novel therapies. Several candidates are progressing through the clinical trial process, generating significant market anticipation. Among them, JX10, a promising drug with both thrombolytic and anti-inflammatory properties, is currently in Phase II trials, while the neuroprotective agent Nelonemdaz has advanced to the critical Phase III stage. Adding to the momentum, an investigational drug known as AB126 is scheduled to commence a Phase I/II clinical trial in the first half of 2024. This wave of innovation is already impacting clinical practice, as highlighted by NICE's official recommendation in July 2024 to use tenecteplase for acute ischaemic stroke in adults. New Surgical and Drug Therapies Redefine Hemorrhagic Stroke Intervention Strategies Progress in managing hemorrhagic stroke is accelerating, creating new opportunities within the stroke diagnostic and therapeutic market. A landmark 2024 study has demonstrated for the first time the benefit of a standardized, image-guided microsurgical technique for clot removal over medical management alone, specifically leading to better six-month outcomes for patients with lobar hemorrhage. On the pharmaceutical front, for patients experiencing major intracranial bleeding related to Factor Xa inhibitors, the reversal agent andexanet alfa achieved hemostasis in a significant 67% of patients in a key trial. Another major advancement is seen in the treatment of subacute and chronic subdural hematoma, where middle meningeal artery embolization used as an adjunct to surgery drastically reduces the likelihood of recurrence. The recurrence rate within 90 days plummeted to just 4.1% in the group receiving embolization with surgery, compared to 11.3% in the surgery-only group. Alongside these interventions, research confirms that intensive blood pressure reduction in the initial stages of intracerebral hemorrhage effectively lessens the absolute growth of hematomas. Despite these gains, the precise role of surgery in hemorrhagic stroke continues to be a subject of intense research, shaping the future of the stroke diagnostic and therapeutic market. Telestroke Networks Emerge as a Critical Solution to Access-to-Care Gaps Telemedicine is proving to be an indispensable tool, expanding the reach of the stroke diagnostic and therapeutic market to underserved populations. The integration of telestroke platforms facilitates immediate remote consultations and allows for the continuous monitoring of patients, which is particularly crucial for improving care access in regions with limited specialized healthcare resources. The need for such systems is underscored by persistent gaps in public awareness; one survey revealed that only 38% of people could identify all major stroke symptoms and knew to call emergency services. This knowledge deficit contributes to treatment delays, as patients who arrive at an emergency room within three hours of their first symptoms often experience significantly less disability three months later. A nationwide study in the US highlighted the scale of this problem, finding that 54% of stroke patients arrived at a hospital more than two hours after their symptoms began, with these critical delays being more common among older, female, and Black patients. Telestroke networks directly address this challenge by providing a vital bridge, enabling rapid remote evaluation by neurologists to expedite life-saving treatment decisions. Technology-Infused Rehabilitation Creates New Pathways for Long-Term Stroke Recovery The field of stroke rehabilitation is being reinvented, representing a rapidly evolving segment of the stroke diagnostic and therapeutic market. Robotic devices are becoming central to this new paradigm, delivering the kind of highly targeted and intensive therapy needed to help patients regain critical motor function. A significant market development is the Vivistim Paired VNS System, a surgically implanted device that recently gained FDA approval for chronic stroke patients. This innovative vagus nerve stimulation system is specifically designed for individuals with moderate to severe upper arm impairment six months to over 20 years after their stroke. While the surgical procedure to implant the device has been established for decades, its application for stroke recovery is a novel and promising approach. Following implantation, patients engage in a rigorous six-week intensive rehabilitation program. This is complemented by the growing use of wearable technology, such as inertial measurement units and electromyography sensors, which allow for highly tailored assessments and therapies. Concurrently, home-based rehabilitation programs are gaining significant traction, offering patients a more convenient and cost-effective path to recovery. Advanced Neuroimaging Technologies Provide Unprecedented Clarity in Stroke Diagnosis The diagnostic imaging sector of the stroke diagnostic and therapeutic market is advancing rapidly, with new technologies providing unparalleled insights into the brain to facilitate earlier and more precise diagnoses. High-resolution magnetic resonance imaging (MRI) and computed tomography (CT) scans remain the cornerstones for the early detection and exact localization of stroke lesions. While non-contrast CT is still a primary modality for the initial evaluation of a suspected stroke, recent advances have boosted its overall diagnostic sensitivity to 64% and its specificity to 85%. A major technological leap occurred in December 2023 with the unveiling of the NAEOTOM Alpha, a pioneering diagnostic imaging system poised to set new standards in the field. Simultaneously, automated stroke detection software from leading companies like Brainomix, RapidAI, and is achieving widespread adoption and gaining significant market traction. The integration of artificial intelligence with this imaging data is a game-changer; it can now help clinicians predict the final infarct volume and accurately assess the risk of hemorrhagic transformation. Operator and Hospital Experience Emerge as Key Drivers of Patient Outcomes The correlation between procedural volume and patient outcomes is becoming a critical point of analysis for stakeholders in the stroke diagnostic and therapeutic market. A comprehensive study involving over 3,000 patients revealed a clear benefit associated with experienced clinicians; it found that higher proceduralist volume, defined as performing 18 or more endovascular therapies per year, was directly associated with reduced in-hospital mortality. The data showed that the absolute risk of death was 4.8% lower in this high-volume group. Another study, however, observed a paradoxical relationship where higher-volume hospitals had worse outcomes, a finding likely attributable to these centers treating a greater proportion of severe and complex cases. This was supported by an analysis where the odds of in-hospital mortality actually increased in higher-volume quartiles. A snapshot from Florida in 2019 showed that of the 297 hospitals, 105 performed mechanical thrombectomy. Among these, 54 were classified as high-volume centers (≥15 MTs/year), with a median of 59.5 cases, compared to a median of just two cases at low-volume hospitals. Stroke's Staggering Global Impact Drives Demand for Innovative Care Solutions Stroke persists as a formidable global health crisis, which in turn fuels the immense global stroke diagnostic and therapeutic market. In 2021 alone, there were 93.8 million stroke survivors and 11.9 million new cases, highlighting the immense scale of the issue. The global cost of stroke is now estimated to be over US$890 billion, placing an enormous economic burden on healthcare systems. Ischemic stroke was the predominant type, accounting for 65.3% of all new strokes in 2021, with a slightly higher incidence among males (52.6%). There are significant regional disparities in both incidence and mortality, revealing inequities in access to care. The lowest age-standardized stroke incidence was observed in Luxembourg (57.7 per 100,000), while the Solomon Islands faced the highest rate (355.0 per 100,000). Similarly, Singapore reported the lowest stroke death rate at 14.2 per 100,000, which stands in stark contrast to North Macedonia, the country with the highest mortality rate at 277.4 per 100,000, illustrating the urgent need for globally accessible and effective solutions from the stroke diagnostic and therapeutic market. Tailor This Report to Your Specific Business Needs: Expanding Therapeutic Windows for Intervention Offer Hope for More Patients Recent clinical research is fundamentally challenging and expanding the traditionally accepted timeframes for effective stroke intervention, a development with profound implications for the stroke diagnostic and therapeutic market. The CT for Late Endovascular Reperfusion (CLEAR) study, which enrolled 2,451 patients, was designed specifically to assess the benefits of EVT within an extended time window, suggesting that even patients with a large ischemic core may still benefit. This is reinforced by a propensity score-matched analysis which found that approximately one-third of large vessel occlusion patients with persistent deficits beyond the 16-hour mark still met the stringent criteria for late-window trials like DAWN or DEFUSE 3. When EVT was performed in these late-presenting patients, it resulted in 11.08-fold higher odds of achieving a good functional outcome. These findings add urgency to the treatment process, as demonstrated by foundational studies like MR CLEAN, which showed that every single hour of delay in achieving reperfusion led to a 7.7% decreased probability of the patient regaining functional independence. Likewise, the REVASCAT trial quantified the cost of delay, showing a 26% decrease in the likelihood of a favorable outcome for every 30-minute delay in reperfusion. Top Companies in Stroke Diagnostic and Therapeutic Market Abbott Laboratories Boston Scientific Corporation Cerebrotech Medical Systems, Inc. Cordis Corporation GE Healthcare Genentech Inc. Gowerlabs Hyperfine MRI Koninklijke Philips N.V. Medfield Diagnostics Medtronic plc. Merck & Co., Inc. Neural Analytics NIRX Samsung Neurologica Siemens AG Stryker Corporation Other Prominent Players Market Segmentation Overview By Type Diagnostics Magnetic Resonance Imaging (MRI) Computed Tomography Scan (CT scan) Electrocardiography Carotid Ultrasound Cerebral Angiography Others Therapeutics Tissue Plasminogen Activator Antiplatelet Antihypertensive Anticoagulant By Application Hemorrhagic Stroke Ischemic Stroke By Region North America Europe Asia Pacific Middle East Africa South America Want Deeper Insights? Book a Free Call with an Expert: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
12-07-2025
- Mint
Google Pixel 10 prototype surfaces on Chinese site ahead of official launch
Google's Pixel 10 series is expected to launch soon, and new information has appeared from an unexpected source. A Chinese auction site called Xianyu listed what is said to be a Pixel 10 prototype motherboard. The listing, spotted by 9to5Google, claims the part is from an EVT (Engineering Validation Testing) unit, a late stage before mass production. The seller describes the item as a Pixel 10 motherboard from an Engineering Validation Testing (EVT) unit. EVT is a stage in the product development process just before mass production. The listing also includes photos of the phone, which shows a design similar to previous Pixel models, with rounded corners, flat edges, and the familiar horizontal camera bump on the back. The device bears the Google "G" logo. The images reveal that the device has three camera lenses. This suggests that the Google Pixel 10 could include a telephoto lens, an upgrade from the Pixel 9's dual-camera setup, which aligns with earlier rumours about camera improvements in the new model. The motherboard carries a Tensor G5 label and an SEC marking, which some experts say indicates Samsung manufactured the chip. This detail raises questions because several reports suggest Google plans to switch production of its Tensor chips from Samsung to Taiwan Semiconductor Manufacturing Company (TSMC), starting with the G5 chip. It is unclear how recent this prototype is or if Google initially considered continuing with Samsung before deciding to move to TSMC. The seller's listing focuses heavily on warning against scammers and does not clarify these points. The authenticity of this prototype and the associated chip details will be confirmed when Google officially unveils the Pixel 10 series on August 13. Until then, the images and information from the auction remain unofficial but provide an early glimpse into what the next Pixel may offer.
Tom's Guide
03-07-2025
- Tom's Guide
iPhone Fold just hit a major milestone — but it's bad news for iPad Fold
There's good news for those of you hoping to pick up the iPhone Fold as soon as possible. Rumor has it that the phone could launch as early as next year, and according to a new report Apple now has a functioning prototype of the device. According to DigiTimes, Apple kickstarted the iPhone Fold's prototyping phase last month, which is expected to continue until the end of the year. Once complete, the phone should enter the Engineering Verification Test (EVT) phase, which is another crucial step ahead of mass production. If that all goes according to plan, it means the iPhone Fold may well go on sale alongside the iPhone 18 series next September. There's no guarantee things will go swimmingly, but it means that after a fairly long and troubled-sounding development, the iPhone Fold should now be on track to arrive in the near future. Sadly it sounds like the same can't be said for Apple's foldable iPad. There had been some uncertainty as to whether the iPhone Fold would arrive before or after the iPad Fold —but now it sounds like the iPhone is more of a certainty. As DigiTimes reports, Apple "has decided to pause progress on the larger foldable device for the time being." Industry experts claim this is due to a combination of manufacturing difficulties, increased production costs and the fact there isn't a whole lot of demand for a larger foldable tablet. Predictions for the tablet have been a little bit inconsistent, with the likes of Jeff Pu promising a 2026 launch while Mark Gurman said 2028 at the absolute earliest. But with this latest report the timeline is increasingly unclear. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Then again it makes sense that Apple would want to nail the iPhone Fold before it invests too heavily in a larger version, After all, the foldable iPhone screen will essentially turn the phone into a tablet that will fill part of the niche currently occupied by non-folding iPads. On top of that, it's unclear how successful the iPhone Fold will be. With reports claiming only 15-20 million units have been ordered for the first few years of the foldable's lifespan, Apple's clearly playing it safe with the iPhone Fold — at least at first. Which means pausing development on the second foldable makes perfect sense. In the meantime be sure to check out our iPhone Fold hub for all the latest news and rumors about the Apple foldable.
Hospitality Net
13-06-2025
- Business
- Hospitality Net
Stella Blythe has been appointed Senior Vice President of Development, Asia at EVT Singapore
EVT welcomes Stella Blythe as Senior Vice President of Development, Asia. Part of the team leading EVT's expansion into the dynamic and fastest-growing region of the world, Blythe brings over a decade of knowledge in hotel valuation and brokerage experience across EMEA and APAC. Named the International Society of Hospitality Consultants Rising Star in 2024, Blythe was most recently Director of Hotels & Hospitality, Capital Markets at CBRE Asia, based in Singapore. Blythe officially joins the EVT team on 3rd of June, based in the QT Singapore office.
The Age
13-06-2025
- Business
- The Age
Property veteran buys $66.5m freezer warehouse; Thredbo owner to sell $300m block; Pearl Bondi gets approval
EVT, run by long-standing chairman and major shareholder, the rich lister Alan Rydge, is selling the property to focus on its hotel division which includes brands such as QT and Rydges, and Thredbo ski resort. The latest annual report has the property portfolio worth about $2.3 billion. Loading It comes with a stage 2 development approval for a 43-level, 28,283-square-metre mixed-use tower including residential, hotel, cinema, and retail space. The high-rise levels of the tower will include 98 luxury apartments, totalling 12,671 square metres. In addition, an 11,068-square-metre five-star lifestyle hotel will occupy the low to mid-rise section of the tower, featuring 285 premium rooms with bar, restaurant and conference facilities. The retail part of the development will include tenancies with street frontage along George Street of 405 sq m, and 333 sq m along Albion Lane. The existing Event Cinemas complex currently operates sixteen screens across the 525 and 505 George Street properties. The full complex will remain operational until 525 George's redevelopment starts, after which fewer screens will operate. CBRE's Michael Simpson, Ben Wicks and Tom Gibson are managing the sale. New airport The hotel sector is anticipating a jump in demand following the completion of the construction of the Western Sydney's International (Nancy-Bird Walton) Airport terminal in Badgerys Creek. Accommodation Australia chief executive James Goodwin said it was encouraging to see the momentum building for the new airport. 'We know each and every international flight will go a long way to help fill more hotel rooms and create more secure jobs in the accommodation sector, not only in Sydney, but right across the country – and that's good news for the entire sector,' Goodwin said. The new airport is on track to open for domestic, international and air cargo services in late 2026. Bondi build Central Elements has expanded its presence in the eastern suburbs with approval being gained for a $150 million development of luxury apartments. Located at 20-22 Sandridge Street and 21 Wilga Street, the Pearl Bondi complex will overlook the beach. It was designed by architects MHNDU and the interiors by Madeleine Blanchfield. Building is expected to start later this year on the amalgamated 2050-square-metre site. There will be seven three-bedroom residences – two houses and five house-size apartments on the oceanfront. Parramatta lease Space within the recently refurbished Parramatta Town Hall is up for lease. Completed in 1883, the Victorian Free Classical architectural style building was built to serve as the town hall and municipal chamber for the Borough of Parramatta. The space within 7 Parramatta Square, known as the Jubilee Hall, has an internal footprint of 122 sq m, with outdoor licensed seating of 57 sq m fronting the adjacent laneway and neighbouring the recently opened Ippudo Ramen restaurant. Colliers' Janelle Coorey and Liz Chuck have the listing.
